Reported Q: Q2 2026 Rev YoY: -26.3% EPS YoY: +70.7% Move: -5.05%
Tilray Brands Inc
2HQ.DE
โ‚ฌ0.680 -5.05%
Exchange XETRA Sector Healthcare Industry Drug Manufacturers Specialty Generic
Q2 2026
Published: Jan 8, 2026

Company Status Snapshot

Fast view of the latest quarter outcome for 2HQ.DE

Reported

Report Date

Jan 8, 2026

Quarter Q2 2026

Revenue

217.51M

YoY: -26.3%

EPS

-0.41

YoY: +70.7%

Market Move

-5.05%

Previous quarter: Q1 2026

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $217.51M down 26.3% year-over-year
  • EPS of $-0.41 increased by 70.7% from previous year
  • Gross margin of 26.4%
  • Net income of -43.51M
  • "N/A" - N/A
2HQ.DE
Company 2HQ.DE

Executive Summary

Tilray Brands reported QQ2 2026 results (2HQ.DE) with revenue of $217.5 million and a gross profit of $57.5 million, producing a gross margin of 26.4%. The quarter delivered a net loss of $43.5 million and an EBITDA loss of $22.3 million, with earnings per share of -$0.41. Year-over-year revenue declined 26.3% and quarter-over-quarter revenue declined 24.4%, reflecting ongoing market softness in cannabis and broader consumer headwinds. Despite the top-line pressure, operating income improved year-over-year by 62.3% but remained negative, underscoring continued structural cost burdens and the higher fixed-cost base. On the cash-flow front, operating cash flow was negative by $8.5 million, while financing activities contributed $48.1 million, leaving a net cash decrease of $18.1 million for the period and a year-end cash balance of approximately $246.7 million. Free cash flow was -$8.5 million, signaling limited liquidity runway without improvements in revenue or margin and/or additional financing.

The results emphasize Tilrayโ€™s ongoing strategic mix across Cannabis, Beverage Alcohol, Distribution, and Wellness. The companyโ€™s liquidity position provides optionality to fund near-term operations and selective investments, but the near-term trajectory hinges on revenue stabilization, gross margin expansion, and disciplined cost management. In the absence of an earnings-call transcript in the provided data, the qualitative read relies on reported figures and implied operational levers. Investors should monitor progress on cost reductions, product mix optimization, potential market expansion, and any management commentary on strategic priorities and capital allocation.

Key Performance Indicators

Revenue
Decreasing
217.51M
QoQ: -24.42% | YoY: -26.28%
Gross Profit
Decreasing
57.50M
26.43% margin
QoQ: -27.17% | YoY: -32.85%
Operating Income
Increasing
-22.28M
QoQ: -875.28% | YoY: 62.27%
Net Income
Increasing
-43.51M
QoQ: -9 736.72% | YoY: 63.55%
EPS
Increasing
-0.41
QoQ: -10 150.00% | YoY: 70.69%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q2 2026 217.51 -0.41 -26.3% View
Q1 2026 287.78 0.00 +6.7% View
Q4 2025 308.10 -17.80 +34.0% View
Q3 2025 185.78 -0.87 -1.4% View
Q2 2025 210.95 -0.10 +8.9% View